Cynthia Corbitt

Dr. Cynthia Corbitt

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2006 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VSVirgilo A. Salvo
Virgilo A. Salvo
SBStephen M. Boué
Stephen M. Boué
JFJuan P. Fonseca
Juan P. Fonseca
SESteven Elliott
Steven Elliott
CCCynthia Corbitt
Cynthia Corbitt
MBMatthew E. Burow
Matthew E. Burow
Purpose: We have identified the phytoalexin compounds glyceollins I, II, and III, which exhibit marked antiestrogenic effects on estrogen receptor function and estrogen-dependent tumor growth in vivo. The purpose of this study was to investigate the interactions among the induced soy phytoalexins glyceollins I, II, and III on the growth of estrogen-dependent MCF-7 breast cancer and BG-1 ovarian cancer cells implanted in ovariectomized athymic mice. Experimental Design: Four treatment groups for each cell line were used: vehicle control, 20 mg/kg/mouse/d glyceollin mixture injection, 0.72 mg estradiol (E2) implant, and E2 implant + 20 mg/kg/mouse/d glyceollin injection. Results: Treatment with glyceollin suppressed E2-stimulated tumor growth of MCF-7 cells (−53.4%) and BG-1 cells (−73.1%) in ovariectomized athymic mice. These tumor-inhibiting effects corresponded with significantly lower E2-induced progesterone receptor expression in the tumors. In contrast to tamoxifen, the glyceollins had no estrogen-agonist effects on uterine morphology and partially antagonized the uterotropic effects of estrogen. Conclusions: These findings identify glyceollins as antiestrogenic agents that may be useful in the prevention or treatment of breast and ovarian carcinoma.

1 September 2007 in American Museum Novitates
Verified
Journal Article
Closed access
GRGuillermo W. Rougier
Guillermo W. Rougier
AGAlberto Garrido
Alberto Garrido
LGLeandro Gaetano
Leandro Gaetano
PPPablo F. Puerta
Pablo F. Puerta
CCCynthia Corbitt
Cynthia Corbitt
MNMichael J. Novacek
Michael J. Novacek

28 June 2021 in Cells
Verified
Journal Article
Open access
PDF file
SSSarama Saha
Sarama Saha
PRPartha Roy
Partha Roy
CCCynthia Corbitt
Cynthia Corbitt
Sham KakarSham Kakar
Sham Kakar
Infertility creates an immense impact on the psychosocial wellbeing of affected couples, leading to poor quality of life. Infertility is now considered to be a global health issue affecting approximately 15% of couples worldwide. It may arise from factors related to the male (30%), including varicocele, undescended testes, testicular cancer, and azoospermia; the female (30%), including premature ovarian failure and uterine disorders; or both partners (30%). With the recent advancement in assisted reproduction technology (ART), many affected couples (80%) could find a solution. However, a substantial number of couples cannot conceive even after ART. Stem cells are now increasingly being investigated as promising alternative therapeutics in translational research of regenerative medicine. Tremendous headway has been made to understand the biology and function of stem cells. Considering the minimum ethical concern and easily available abundant resources, extensive research is being conducted on induced pluripotent stem cells (iPSCs) and mesenchymal stem cells (MSC) for their potential application in reproductive medicine, especially in cases of infertility resulting from azoospermia and premature ovarian insufficiency. However, most of these investigations have been carried out in animal models. Evolutionary divergence observed in pluripotency among animals and humans requires caution when extrapolating the data obtained from murine models to safely apply them to clinical applications in humans. Hence, more clinical trials based on larger populations need to be carried out to investigate the relevance of stem cell therapy, including its safety and efficacy, in translational infertility medicine.

1 January 2010 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
MZM. Carla Zimmermann
M. Carla Zimmermann
Syreeta L TilghmanSyreeta L Tilghman
Syreeta L Tilghman
SBStephen M. Boué
Stephen M. Boué
VSVirgilio A. Salvo
Virgilio A. Salvo
SESteven Elliott
Steven Elliott
Matthew BurowMatthew Burow
Matthew Burow
Glyceollins, a group of novel phytoalexins isolated from activated soy, have recently been demonstrated to be novel antiestrogens that bind to the estrogen receptor (ER) and inhibit estrogen-induced tumor progression. Our previous publications have focused specifically on inhibition of tumor formation and growth by the glyceollin mixture, which contains three glyceollin isomers (I, II, and III). Here, we show the glyceollin mixture is also effective as a potential antiestrogenic, therapeutic agent that prevents estrogen-stimulated tumorigenesis and displays a differential pattern of gene expression from tamoxifen. By isolating the individual glyceollin isomers (I, II, and III), we have identified the active antiestrogenic component by using competition binding assays with human ERα and in an estrogen-responsive element-based luciferase reporter assay. We identified glyceollin I as the active component of the combined glyceollin mixture. Ligand-receptor modeling (docking) of glyceollin I, II, and III within the ERα ligand binding cavity demonstrates a unique type II antiestrogenic confirmation adopted by glyceollin I but not isomers II and III. We further compared the effects of glyceollin I to the antiestrogens, 4-hydroxytamoxifen and ICI 182,780 (fulvestrant), in MCF-7 breast cancer cells and BG-1 ovarian cancer cells on 17β-estradiol-stimulated expression of progesterone receptor and stromal derived factor-1α. Our results establish a novel inhibition of ER-mediated gene expression and cell proliferation/survival. Glyceollin I may represent an important component of a phytoalexin-enriched food (activated) diet in terms of chemoprevention as well as a novel therapeutic agent for hormone-dependent tumors.

1 July 2017 in Journal of Functional Foods
Verified
Journal Article
Closed access
SBSanaya F. Bamji
Sanaya F. Bamji
CCCynthia Corbitt
Cynthia Corbitt

1 October 2010 in Journal of Chemical Neuroanatomy
Verified
Journal Article
Closed access
JWJared K. Woods
Jared K. Woods
PDPierre Deviche
Pierre Deviche
CCCynthia Corbitt
Cynthia Corbitt